Arcoma AB
Arcoma AB is a healthcare equipment company that develops and commercializes advanced medical devices, primarily focused on minimally invasive surgical solutions.
Business. Arcoma AB (ARCOMA.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Arcoma AB is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Arcoma AB (ARCOMA.ST) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Arcoma AB is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Arcoma maintains a strong liquidity position with a current ratio of 3.49 and no long-term debt, indicating a conservative capital structure. The company's liquidity risk is assessed as low, supported by positive operating and free cash flows of 18.72 million SEK and 6.75 million SEK, respectively.
Profitability metrics show a return on equity of 6.73% and a return on assets of 5.2%, which are in line with the industry's median performance for advanced medical equipment firms. The company's operating margin of 4.8% and net margin of 3.8% reflect a typical margin profile for firms in this capital-light, high-margin industry.
Arcoma's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company operates primarily in the Nordic region, which represents a relatively small and stable market for medical equipment. This lack of geographic diversification may limit growth potential in the long term.
The company's revenue growth outlook for the current fiscal year is modest, with analysts forecasting a 3.2% increase to 135 million SEK. This aligns with the company's historical growth trajectory, which has been relatively flat over the past three years. No significant capital expenditures are expected in the near term, as the company's capex has been negative in recent periods.
Arcoma's risk profile is characterized by low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains debt-free. The absence of long-term debt and the presence of positive free cash flow reduce the likelihood of near-term dilution. No recent equity issuance or ATM programs have been disclosed.
Recent filings and transcripts indicate that Arcoma is focused on expanding its product portfolio and strengthening its position in the Nordic market. The company has not disclosed any material regulatory or litigation risks in its latest filings.
- Arcoma maintains a strong liquidity position with a current ratio of 3.49 and no long-term debt.
- The company's profitability metrics are in line with industry medians, with a return on equity of 6.73% and a return on assets of 5.2%.
- Revenue is concentrated in a single business segment with no disclosed geographic diversification.
- Analysts forecast modest revenue growth of 3.2% for the current fiscal year.
- The company's risk profile is low, with no immediate liquidity or dilution flags.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,55 |
| Revenue | —no estimate | —no estimate | 135,0M SEK |
| Operating income | —no estimate | —no estimate | 10,0M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Arcoma AB Market data — financials · 2026-05-27
- Arcoma AB Market data — analyst estimates · 2026-05-27